Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L6OA
|
||||
| Former ID |
DPR000023
|
||||
| Drug Name |
BL-1020
|
||||
| Synonyms |
BL 1020; Perphenazine 4-aminobutyrate; Butanoic acid, 4-amino-, 2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Phase 2 | [1] | ||
| Company |
BioLineRx
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H34ClN4O3S-
|
||||
| CAS Number |
CAS 1027512-25-9
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [1] | |
| Gamma-aminobutyric acid receptor | Target Info | Agonist | [1] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.